PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults
NCT06863363 on ClinicalTrials.gov · last registry update 2025-03-07
An unusually large phase 4: 212 participants, more than double the 75 typical for the stage. Primary outcome, as filed: The change in lean body weight (kg) from baseline. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Shanghai Zhongshan Hospital
- Sponsor type
- Other
- Enrollment
- 212
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
The change in lean body weight (kg) from baseline
Conditions studied
Non-diabetic Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.